PhenoVista Biosciences Announces $1.4M Phase 2 SBIR Grant for Phenotypic Drug Screening in Alzheimer's Disease

August 13, 2020 9:00 AM / by PhenoVista Biosciences

SAN DIEGO, Calif.– August 13, 2020 – PhenoVista Biosciences announced today that The National Institutes of Health (NIH) National Institute for Aging (NIA) has awarded the company $1,424,450 under the Small Business Innovative Research (SBIR) program to further develop iPSC-derived neuronal models of Alzheimer's Disease for phenotypic drug screening.  PhenoVista proposes to generate and refine both 2D and 3D models for Alzheimer’s Disease that better reflect the complexity of the disease, and use these models for drug discovery and development applications.

“We believe there is an opportunity to improve how drug discovery is done for this devastating disease. Successful development and commercialization of next-generation, high-performance technology for modeling both disease biology and the effects of investigational drugs on neurons will help improve the development process for new therapies and take advantage of our experience in neuronal cultures, fluorescence microscopy, and machine learning/AI applications,” said Dr. James Evans, CEO of PhenoVista.

PhenoVista’s core expertise is combining physiologically-relevant 2D and 3D cell models and quantitative fluorescence imaging into phenotypic assays for drug discovery, medical device development, toxicity testing, and other applications. Support from the NIH is an important part of the Company’s overall strategy to develop new assays for challenging diseases and commercialize them through partnerships. This research will be supported by the NIA of the NIH under Award Number 2R44AG058520-02.

About PhenoVista Biosciences

PhenoVista Biosciences is the leading provider of custom imaging-based phenotypic assay services. With a collaborative and scientifically driven project design and management approach, PhenoVista has a proven track record of delivering high quality data from robust and scalable assays. Phenovista’s key advantage lies in the ability of their industry-trained scientists to combine world-class understanding of diverse biological systems with cutting-edge quantitative imaging to deliver clear, actionable output data. For more information, please visit Follow PhenoVista on LinkedIn, Twitter, and Facebook.


Raymond Price, PhD
VP, Business Development
PhenoVista Biosciences, LLC.

Scroll to Top